Baxter Theranova: More Middle Molecules, Less Albumin Loss
Baxter’s new dialyzer mimics the function of natural kidneys more closely, removing more middle molecules with no replacement fluid needed—and minimal loss of vital albumin. The new expanded hemodialysis (HDx) therapy has been tested in the UK, where it reduced beta-2 microglobulin levels by more than 11%
Read the full article » | Posted 12-14-2017
Related Articles
- VenoStent, Inc. is Recruiting Patients for a Clinical Trial of the SelfWrap Posted 10-14-2025
- Diality Treated its First Patient in the Moda-flx Home IDE PRESCRIBE Cinical Trial Posted 10-14-2025
- eGenesis Announces IND Clearance for EGEN-2784 in Kidney Transplant Posted 09-15-2025
- The First Artificial Kidney Built in Canada has Ties to London: A Revolution in Care for Patients with Kidney Failure Posted 09-15-2025

